Positive Buy Rating for UroGen Pharma Driven by Promising UGN-102 Prospects and Strong Financial Position

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Urogen Pharma (URGN – Research Report) today and set a price target of $55.00.

Ram Selvaraju has given his Buy rating due to a combination of factors including the upcoming FDA Advisory Committee meeting for UGN-102, which is expected to proceed positively. The meeting will review the New Drug Application for UGN-102, a treatment for recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer, and the data supporting this application is considered highly compelling. The pivotal Phase 3 ENVISION trial demonstrated strong efficacy, with a high complete response rate and duration of response, which bolsters confidence in the potential approval of the drug.
Additionally, UroGen Pharma’s financial position appears robust, with sufficient cash reserves to support the launch of UGN-102. The company has reported financial results that align with expectations, and they are preparing for a U.S. market launch in the third quarter of 2025. The existing commercial infrastructure and experience with their lead product, JELMYTO, further support the anticipated successful rollout of UGN-102. These factors contribute to the positive outlook and Buy rating for Urogen Pharma’s stock.

Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Axsome Therapeutics, and Niagen Bioscience. According to TipRanks, Selvaraju has an average return of 8.8% and a 38.79% success rate on recommended stocks.

In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $35.00 price target.